Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Aerie Pharmaceuticals, Inc. (NASDAQ: AERI).

Full DD Report for AERI

You must become a subscriber to view this report.


Recent News from (NASDAQ: AERI)

3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . And...we're back! I've spent the last half a week traveling without Internet,...
Source: SeekingAlpha
Date: May, 17 2018 08:00
Wired News - Eli Lilly's Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache
Stock Monitor: Aerie Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?sym...
Source: ACCESSWIRE IA
Date: May, 17 2018 07:30
Aerie Pharma submits U.S. application for eye drop Roclatan
Aerie Pharmaceuticals (NASDAQ: AERI ) has filed a marketing application with the FDA seeking approval for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a once-daily eyedrop to reduce intraocular pressure in patients with glaucoma or ocular hypertension. More news on...
Source: SeekingAlpha
Date: May, 15 2018 07:42
Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glau...
Source: Business Wire
Date: May, 15 2018 06:30
Aerie Pharmaceuticals' (AERI) CEO Vincente Anido on Q1 2018 Results - Earnings Call Transcript
Aerie Pharmaceuticals, Inc. (AERI) Q1 2018 Earnings Conference Call May 08, 2018, 17:00 ET Executives Richard Rubino - CFO & Secretary Vincente Anido - Chairman & CEO Thomas Mitro - President & COO Analysts Adnan Butt - Guggenheim Securities Andrew Santos - S...
Source: SeekingAlpha
Date: May, 09 2018 02:43
Aerie Pharmaceuticals beats by $0.04
Aerie Pharmaceuticals (NASDAQ: AERI ): Q1 EPS of -$0.83 beats by $0.04 . More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 16:24
Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 8 th , at 5:00 p.m. ET Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glau...
Source: Business Wire
Date: May, 08 2018 16:01
Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie Pharmaceuticals, Forrester Research, and Diamond Hill Investment Group - Discovering Underlying Factors of Influence
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Roper Technologies, Inc. (NYSE:ROP), Inter Parfums, Inc. (NASDAQ:IPAR), Su...
Source: GlobeNewswire
Date: May, 03 2018 08:10
Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay
Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned ...
Source: SeekingAlpha
Date: May, 02 2018 08:00
Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of Con...
Source: Business Wire
Date: May, 01 2018 06:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1851.2551.1551.9550.60248,199
2018-05-1751.2551.1551.9550.60248,199
2017-06-2051.8550.5053.47550.20549,619
2017-06-1950.4051.4051.4549.175575,657
2017-06-1650.0550.0550.9049.451,292,036

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2324,04353,42145.0066Short
2018-05-225,70046,08712.3679Cover
2018-05-2137,37987,87842.5351Short
2018-05-1857,76972,64779.5201Short
2018-05-1711,43924,32347.0296Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AERI.


About Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Logo for Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $2,010,188,610 - 05/11/2018
  • Issue and Outstanding: 39,492,900 - 02/14/2018

 


Recent Filings from (NASDAQ: AERI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 13 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (NASDAQ: AERI)

Daily Technical Chart for (NASDAQ: AERI)


Stay tuned for daily updates and more on (NASDAQ: AERI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AERI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AERI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AERI and does not buy, sell, or trade any shares of AERI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/